Ensysce Biosciences (ENSC) Other Non-Current Liabilities (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Other Non-Current Liabilities of $35.0 for Q3 2025, down 98.91% year-over-year from $3213.0 in Q3 2024, and down 96.61% quarter-over-quarter from $1033.0 in Q2 2025.
Ensysce Biosciences (ENSC) Other Non-Current Liabilities (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Other Non-Current Liabilities for 8 consecutive years, with $35.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non-Current Liabilities fell 98.91% year-over-year to $35.0; the TTM figure through Sep 2025 stood at $35.0 (down 98.91% YoY), while the FY2024 annual figure was $10096.0, down 61.74% from the prior year.
- Other Non-Current Liabilities retreated to $35.0 in Q3 2025 per ENSC's latest filing, from $1033.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.3 million in Q1 2021 and bottomed at $35.0 in Q3 2025.
- Historically, Other Non-Current Liabilities has averaged $902340.3 across 5 years, with a median of $69507.0 in 2023.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 646.74% in 2025 and fell as far as 98.91% in 2025.
- Ensysce Biosciences' Other Non-Current Liabilities stood at $3.7 million in 2021, then tumbled by 91.5% to $310346.0 in 2022, then slumped by 91.5% to $26388.0 in 2023, then slumped by 61.74% to $10096.0 in 2024, then sank by 99.65% to $35.0 in 2025.
- Business Quant data shows ENSC's Other Non-Current Liabilities at $35.0 in Q3 2025, $1033.0 in Q2 2025, and $130180.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 35.00 |
| Jun 30, 2025 | 1,033.00 |
| Mar 31, 2025 | 130,180.00 |
| Dec 31, 2024 | 10,096.00 |
| Sep 30, 2024 | 3,213.00 |
| Jun 30, 2024 | 9,615.00 |
| Mar 31, 2024 | 17,433.00 |
| Dec 31, 2023 | 26,388.00 |
| Sep 30, 2023 | 30,473.00 |
| Jun 30, 2023 | 47,696.00 |
| Mar 31, 2023 | 91,318.00 |
| Dec 31, 2022 | 310,346.00 |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 360,797.00 |
| Mar 31, 2022 | 871,409.00 |
| Dec 31, 2021 | 3.65 Mn |
| Sep 30, 2021 | 957,099.00 |
| Mar 31, 2021 | 8.31 Mn |
| Dec 31, 2020 | 6.26 Mn |
| Dec 31, 2019 | 7.17 Mn |